GILD

Gilead Sciences
D

GILD

92.570
USD
1.46
(1.60%)
مغلق
حجم التداول
315,478
الربح لكل سهم
4
العائد الربحي
3.33
P/E
1,029
حجم السوق
115,366,830,382
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأفكار والتحليلات
    هشام منسي
    هشام منسي
    منذ شهر
    buy
    GILD
    GILD
    2024-10-30 14:50
    GILD Chart
    المزيد
أصول ذات صلة
    ABBV
    ABBV
    4.190
    (2.44%)
    175.700 USD
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BIIB
    BIIB
    -0.780
    (-0.53%)
    146.590 USD
    BMY
    BMY
    0.990
    (1.76%)
    57.280 USD
    GSK
    GSK
    0.155
    (0.46%)
    33.595 USD
    JNJ
    JNJ
    0.890
    (0.62%)
    144.450 USD
    MRK
    MRK
    -1.390
    (-1.40%)
    98.150 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    المزيد
الأخبار

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).